Caladrius Biosciences to Participate at Upcoming June Conferences

BASKING RIDGE, N.J., June 01, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a clinical stage development company with a cell therapy pipeline focused on immune modulation and select cardiovascular indications, announces today that the Company’s leadership will participate at the following upcoming June conferences:

7^th Annual LD Micro Invitational

• Date and Time: Tuesday, June 6, 2017, 8:30 AM PT
• Venue: Luxe Sunset Hotel, Los Angeles, California
• Website: https://www.ldmicro.com/events
• Presentation: Company Presentation
• Speaker: David J. Mazzo, Chief Executive Officer, Caladrius
• Webcast: http://www.caladrius.com/events

14^th International Symposium on Stem Cell Therapy & Cardiovascular Innovations

• Venue: Hospital General Universitario Gregorio Maranon, Madrid, Spain
• Website: http://cardiovascularcelltherapy.com/wp-content/uploads/2010/06/Preliminary-Agenda.-June-2017-version-reducida-2.pdf

Session 1

• Date and Time: Thursday, June 15, 2017, 12:00 PM CET
• Panel: What’s New in Cardiovascular Regenerative Medicine?
• Panelist: Douglas W. Losordo, MD, Chief Medical Officer, Caladrius

Session 2

• Date and Time: Thursday, June 15, 2017, 4:20 PM CET
• Panel: The 2017 Debate
• Panelist: Douglas W. Losordo, MD, Chief Medical Officer, Caladrius

About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. For more information on Caladrius please visit www.caladrius.com.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 17, 2017, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

Contacts: Investors: LHA Investor Relations Anne Marie Fields Senior Vice President Phone: +1-212-838-3777 Email: afields@lhai.com                    Media: Caladrius Biosciences, Inc. Terrance Beckett Communications and Marketing Phone: + 1-646-434-2681 Email: tbeckett@caladrius.com